Cisplatin vs Paclitaxel for Triple Negative Breast Cancer

Status Completed

Clinical Trial Summary

This is a phase II study randomizing patients with stage I with T1 > 1.5 cm, stage II or III triple negative breast cancer (TNBC) to preoperative cisplatin versus paclitaxel. The study is designed to evaluate the ability of the Homologous Recombination Deficiency (HRD) assay to predict pathologic response to preoperative chemotherapy.

Clinical Trial Description

Cisplatin and paclitaxel are active in triple-negative breast cancer (TNBC). Despite different mechanisms of action, effective predictive biomarkers to preferentially inform drug selection have not been identified. The homologous recombination deficiency (HRD) assay (Myriad Genetics, Inc.) detects impaired double-strand DNA break repair and may identify patients with BRCA1/2-proficient tumors that are sensitive to DNA-targeting therapy. The primary objective of TBCRC 030 was to detect an association of HRD with pathologic response (residual cancer burden (RCB)-0/1) to singleagent cisplatin or paclitaxel. This prospective phase II study enrolled patients with germline BRCA1/2 wild-type/unknown stage I-III TNBC in a 12-week randomized study of preoperative cisplatin or paclitaxel. The HRD assay was carried out on baseline tissue; positive HRD was defined as a score >=33. Crossover to an alternative chemotherapy was offered if there was inadequate response. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01982448
Study type	Interventional
Source	Dana-Farber Cancer Institute
Contact
Status	Completed
Phase	Phase 2
Start date	April 2014
Completion date	August 2020

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05174832` - Induction of Cisplatin/Nab-paclitaxel/Pembrolizumab Followed by Olaparib/Pembrolizumab Maintenance in mTNBC Patients	Phase 2
Active, not recruiting	`NCT03667716` - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.	Phase 1
Withdrawn	`NCT03634150` - Safety and Efficacy of IV Nerofe™ Followed by Doxorubicin, In Metastatic Ovarian Cancer and Triple Negative Breast Cancer	Phase 1/Phase 2
Recruiting	`NCT03348098` - Clinical Study of Neoadjuvant Therapy With Apatinib and Paclitaxel in Local Advanced Triple-negative Breast Cancer	Phase 2
Completed	`NCT04032080` - LY3023414 and Prexasertib in Metastatic Triple-negative Breast Cancer	Phase 2
Active, not recruiting	`NCT03170960` - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors	Phase 1/Phase 2
Withdrawn	`NCT02427581` - Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients With Persistent Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy	Phase 1
Recruiting	`NCT03165487` - Comparison of the Breast Tumor Microenvironment
Completed	`NCT02225470` - Eribulin Versus Vinorelbine in Subjects With Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes	Phase 3
Recruiting	`NCT04452370` - Oral Etoposide Combined With Anlotinib in Advanced Triple Negative Breast Cancer	Phase 2
Terminated	`NCT04123704` - Sitravatinib in Metastatic Breast Cancer	Phase 2
Recruiting	`NCT04758780` - Imaging Performance Assessment of 89Zirconium-labelled Girentuximab (89Zr-TLX250) PET-CT in Metastatic Triple Negative Breast Cancer Patients	Phase 2
Withdrawn	`NCT04268693` - Bisphenol and Phthalate Exposures in Triple Negative Breast Cancer
Withdrawn	`NCT03982173` - Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors	Phase 2
Not yet recruiting	`NCT02685657` - Neoadjuvant Chemotherapy Docetaxel With or Without SELUMETINIB in Patients With Triple Negative Breast Cancer	Phase 2
Terminated	`NCT01918306` - GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer	Phase 1/Phase 2
Completed	`NCT01276899` - Study to Identify Molecular Mechanisms of Clinical Resistance to Chemotherapy in Triple Negative Breast Cancer Patients
Completed	`NCT00998036` - Study of Temsirolimus, Erlotinib and Cisplatin in Solid Tumors	Phase 1
Recruiting	`NCT05309655` - Cardiac Outcomes With Near-Complete Estrogen Deprivation	Early Phase 1
Active, not recruiting	`NCT03267316` - A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors	Phase 1/Phase 2